Etanercept is a biotechnological product as it is genetically engineered fusion protein.
It is composed of:
1. Two identical chains of the recombinant human TNF-receptor p75 monomer.
2. Fc domain of IgG1 (human immunoglobulin).
These two are fused together.
Mechanism of action:
Etanercept binds two molecules of TNF thereby resulting in no binding of TNF to cellular receptors.
Etanercept, Infliximab and adalimumab decrease the activity of TNF. TNF is important for immunity system and must rest in the rheumatic synovium for the action to take place.
It is given subcutaneously, 25 mg, two times a week. Maximum serum concentration is obtained within 72 hours after parenteral administration. Its half life is 4-6 days.
Rheumatic and psoriatic arthritis.
No important adverse effects have been found.
In serious type of infections like sepsis, etanercept should not be given to patient.
Etanercept and methotrexate are more effective when used together (than alone) in slowing the
1. Disease process
2. Improvement in function
3. Stoppage of the symptoms.